On Tuesday, Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth across all segments.
Adjusted operating income was $424 million, a decrease of 37.7% on a constant currency basis, reflecting softer U.S. retail and pharmacy performance, lapping the reversal of incentive accruals and prior year sale-leaseback gains, partly offset by cost savings initiatives and improved profitability in the U.S. Healthcare segment.
Adjusted EPS was $0.39, down 40.8%, beating the consensus of $0.36, according to data from Benzinga Pro.
Also Read: Walgreens Agrees To $106.8M Settlement Over Alleged False Billing Claims.
The U.S. Retail Pharmacy segment sales reached $29.5 billion, up 6.5%. Comparable sales ...
